SlowBull
The Business Brief TUESDAY, 1 SEPTEMBER 2026
← All stories
Markets

Alumis’ TYK2 drug fails in key lupus study

1 source ·1 article ·1h ago

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

Alumis’ TYK2 drug fails in key lupus study

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.